The ErbB1-dependent effect of recombinant epidermal growth factor (rEGF) against lapatinib-induced cytotoxicity in Caco-2 human intestinal cells / Raja Nur Firzanah Syaza Raja Sharin ... [et al.]

• 主要な著者: Raja Sharin, Raja Nur Firzanah Syaza (著者), Wan Mohamad Zain, Wan Nor I'zzah (著者), Khan, Jesmine (著者), Ibahim, Mohammad Johari (著者)
• フォーマット: 図書
• 出版事項: Universiti Teknologi MARA, Pulau Pinang, 2022-09.
• 主題: Article; PeerReviewed
• オンライン･アクセス: Link Metadata

Lapatinib, an orally administered dual ErbB1 and ErbB2 tyrosine kinase inhibitor, is an FDA-approved treatment for ErbB2-positive breast tumour. However, diarrhoea is one of the major drawbacks for this treatment. Incidence of lapatinib-induced diarrhoea (LID) has been reported as high as 58-78% of...